Pilot Study on Evaluating the Geroprotective Effect of Metformin

Launched by XUANWU HOSPITAL, BEIJING · Jun 13, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether a medication called metformin can help slow down the aging process in middle-aged and older men. The study aims to find out how effective metformin is at improving key signs of aging and to provide new insights for future treatments targeting aging. The trial is currently looking for male participants aged between 55 and 65, who are generally healthy and able to understand the study requirements.

If you qualify and choose to participate, you will need to attend regular follow-up visits to monitor your health and response to the medication. However, there are certain health conditions and factors that could exclude you from participating, such as severe chronic illnesses, certain heart and lung diseases, or being on specific medications that affect how the body processes glucose. Overall, this study could be an important step towards developing better treatments for aging.

Gender

MALE

Eligibility criteria

• • Inclusion Criteria：
• • 1. Male
• • 2. Age 55-65; 18-28;
• • 3. Able to understand and execute instructions;
• • 4. After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol;
• • 5. Be able to participate in regular follow-up visits.
• • Exclusion Criteria
• • 1. Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine \>1.5 mg/dl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases;
• • 2. BMI\<18.5 or BMI\>30;
• • 3. Persistent alcohol or drug abuse;
• • 4. Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin);
• • 5. Hypersensitivity to metformin or any component of the preparation;
• • 6. Have taken metformin, low-dose aspirin, acarbose, vitamin C in the recent (3 months);
• • 7. Unable to provide informed consent;
• • 8. Other circumstances in which the researcher believes that the physical factors of the participants may adversely affect the research process or results.